Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution Christina Boutsicaris, MD – Loyola University Medical Center
9:00 AM – 11:00 AM ET
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI) Despoina Michailidou, MD – University of Washington
9:00 AM – 11:00 AM ET
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study Nilasha Ghosh, MD – Hospital for Special Surgery
9:00 AM – 11:00 AM ET
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center Bushra Akram, MD – University of Oklahoma Health Sciences Center
9:00 AM – 11:00 AM ET
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology Amy Cunningham-Bussel, MD, PhD – Brigham and Women's
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases Tomohiro Kameda, MD – Kagawa University
9:00 AM – 11:00 AM ET
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors Kevin Lee, MD, BSc – University of Alberta
9:00 AM – 11:00 AM ET
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review Nilasha Ghosh, MD – Hospital for Special Surgery
9:00 AM – 11:00 AM ET
CD6 Is a Target for Cancer Immunotherapy Mikel Gurrea Rubio, PhD – University of Michigan
9:00 AM – 11:00 AM ET
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review Adam Kilian Kilian, MD – George Washington University
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing Sravani Penumarty, MD – UCLA
9:00 AM – 11:00 AM ET
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response Pankti Reid, MD – University of Chicago Medical Center
9:00 AM – 11:00 AM ET
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events David F. Liew, MBBS, FRACP – Austin Health
9:00 AM – 11:00 AM ET
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review Michael Cunningham, MD – UNC Hospitals
